Clinical Research Directory

Inclusion Criteria: 1. Age 18-75 years old, gender unlimited 2. Diagnosed as HCC through pathological or clinical examination 3. BCLC Phase B or C 4. Previously without systematic treatment 5. Irremovable 6. Intended to receive targeted anti-angiogenic drugs combined with immune checkpoint inhibitors for treatment 7. ≥ 1 measurable lesion (RECIST V1.1) 8. ECOG PS 0-1 9. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up. Exclusion Criteria: 1. Received attenuated live vaccine within 4 weeks prior to enrollment or planned during the study period 2. Active, known or suspected autoimmune diseases 3. Known history of primary immunodeficiency 4. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation 5. Pregnant or lactating female patients 6. Uncontrolled concurrent diseases 7. Currently conducting clinical trials for other drugs 8. Other patients deemed unsuitable for inclusion by researchers